BCR signaling in DLBCL cells at baseline or after treatment. BCR signaling in DLBCL at baseline (A) after treatment with ibrutinib in a BTK-sensitive cell (B) or BTK-insensitive cell (D), or after treatment with the pan-SRC inhibitor masitinib (C). Red shading indicates inhibition of protein signaling, and blue shading indicates activation of protein signaling. The extent of shading corresponds with the extent of change. P, phosphorylation sites. Professional illustration by Somersault18:24.